# Cancer Immunology Program - 03

> **NIH NIH P30** · JOHNS HOPKINS UNIVERSITY · 2021 · $36,924

## Abstract

ABSTRACT 
The mission of the Cancer Immunology (CI) Program is to understand the basic biology of the immune 
response to cancer and to use those data to optimize immunotherapy for cancer—first in preclinical models, 
and subsequently through the design and execution of cutting-edge translational clinical trials. The Program, 
formerly led by Drew Pardoll, M.D., Ph.D., and Elizabeth Jaffee, M.D., is now led by Dr. Pardoll and Charles 
Drake, M.D., Ph.D., as Dr. Jaffee assumed the role of Deputy Director of the Sidney Kimmel Comprehensive 
Cancer Center (SKCCC). The Program includes 21 members from seven departments within the Johns 
Hopkins University School of Medicine. National Cancer Institute (NCI) and other peer-reviewed support of 
Program members totals $8.9 million total costs annually, and the Program receives an additional $26.1 million 
annually in nonpeer-reviewed funding. Sixteen members have peer-reviewed funding. The total number of 
publications by Program members is 434, of which 108 (25%) were Intra-Programmatic, 188 (43%) were Inter- 
Programmatic and 142 (33%) were multi-institutional collaborations. Building on basic, translational and clinical 
trials successes over the past five years, the Program seeks to harvest the untapped capacity of the immune 
system's power to provide further durable cancer remission and even cure. The Programs aims are to: 
Aim 1: Continue to unravel basic mechanisms of immune regulation and cancer immunity that will fuel the next 
generation of cancer immunotherapies. 
Aim 2: Utilize appropriate preclinical models to understand and optimize antitumor immunity, including 
identification of the most potent combinatorial approaches, such as vaccines together with checkpoint 
inhibitors. 
Aim 3: Initiate and complete cutting-edge clinical trials, including the incorporation of appropriate translational 
biomarker studies designed to guide, with precision, current and next-generation immunotherapies. In 
particular, the Program will build on studies over the past five years identifying ligands in the tumor 
microenvironment (TME) and on tumor genetics and viral association as predictors of response to checkpoint 
blockade. 
These aims are facilitated by partnerships among laboratory-focused investigators, translational investigators 
in the CI Program and multiple other SKCCC Programs to jointly develop specific preclinical immunotherapy 
strategies and then translate them into the most suitable clinical settings. Notable advances over the past five 
years include 1) the preclinical testing and foundational clinical development of the first anti-PD-1 antibodies in 
cancer therapy, 2) development of the PD-L1 biomarker, 3) demonstration that mismatch repair deficiency 
(MMRd) cancers and virus-associated cancers have a very high response to anti-PD-1, 3) demonstration of 
patient benefit with novel prime-boost vaccine strategies in pancreas cancer, 4) development of marrow- 
infiltrating lymphocytes for...

## Key facts

- **NIH application ID:** 10135907
- **Project number:** 5P30CA006973-58
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** DREW M. PARDOLL
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $36,924
- **Award type:** 5
- **Project period:** 1997-05-07 → 2022-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10135907

## Citation

> US National Institutes of Health, RePORTER application 10135907, Cancer Immunology Program - 03 (5P30CA006973-58). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10135907. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*